AMBARELLA INC

**Signal Note: Driehaus Capital AMBA Initiation** Driehaus' $25.9M position in Ambarella (AMBA) appears misaligned with typical biotech thesis—AMBA is a semiconductor/AI chip designer, not a drug developer. This suggests conviction in AI infrastructure for edge computing or datacenter applications, likely driven by secular AI adoption tailwinds rather than clinical catalysts. The position size indicates Driehaus sees meaningful upside in AMBA's AI chip competitiveness against broader market expansion, though this represents a tactical pivot toward hardware enablement rather than core biotech exposure.